Display options
Cite
Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2(1):e53doi: 10.1038/bcj.2011.51.
Yoshizawa, S., Ohyashiki, J. H., Ohyashiki, M., Umezu, T., Suzuki, K., Inagaki, A., Iida, S., & Ohyashiki, K. (2012). Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood cancer journal, 2(1), e53. https://doi.org/10.1038/bcj.2011.51
Yoshizawa, S, et al. "Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders." Blood cancer journal vol. 2,1 (2012): e53. doi: https://doi.org/10.1038/bcj.2011.51
Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20. PMID: 22829237; PMCID: PMC3270255.
Copy Download .nbib Format: NLM
Share it on

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Blood cancer journal

S Yoshizawa, J H Ohyashiki, M Ohyashiki, T Umezu, K Suzuki, A Inagaki, S Iida, K Ohyashiki

PMID: 22829237 PMCID: PMC3270255 DOI: 10.1038/bcj.2011.51

Abstract

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects (P<0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8(+) or CD4(+) cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients.

References

  1. J Clin Oncol. 2009 Dec 1;27(34):5848-56 - PubMed
  2. Pathol Int. 2010 May;60(5):351-7 - PubMed
  3. J Clin Oncol. 2010 Feb 1;28(4):690-7 - PubMed
  4. Blood. 2011 Jul 14;118(2):413-5 - PubMed
  5. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90 - PubMed
  6. Blood. 2011 May 5;117(18):4696-700 - PubMed
  7. Blood. 2011 May 5;117(18):4701-5 - PubMed
  8. Blood. 2011 May 5;117(18):4691-5 - PubMed
  9. Annu Rev Med. 2009;60:167-79 - PubMed
  10. N Engl J Med. 2011 Mar 17;364(11):1046-60 - PubMed
  11. Nucleic Acids Res. 2011 Sep 1;39(16):7223-33 - PubMed
  12. BMC Res Notes. 2010 Dec 24;3:347 - PubMed
  13. Cell. 2009 Jan 9;136(1):26-36 - PubMed
  14. PLoS One. 2008 Sep 05;3(9):e3148 - PubMed
  15. Circ Res. 2010 Sep 3;107(5):677-84 - PubMed
  16. Gynecol Oncol. 2009 Jan;112(1):55-9 - PubMed
  17. Nat Immunol. 2008 Apr;9(4):405-14 - PubMed
  18. J Biol Chem. 2002 Mar 8;277(10):7875-81 - PubMed
  19. Leukemia. 2009 Jan;23(1):3-9 - PubMed
  20. Blood. 2007 Apr 15;109(8):3489-95 - PubMed
  21. PLoS One. 2009;4(5):e5532 - PubMed
  22. J Transl Med. 2010 Feb 18;8:17 - PubMed
  23. Nat Rev Cancer. 2006 Apr;6(4):259-69 - PubMed
  24. PLoS One. 2011 Feb 24;6(2):e16408 - PubMed
  25. Leukemia. 2009 Oct;23(10):1716-30 - PubMed
  26. Nat Rev Genet. 2004 Jul;5(7):522-31 - PubMed
  27. Nat Cell Biol. 2007 Jun;9(6):654-9 - PubMed
  28. Nature. 2008 Feb 28;451(7182):1125-9 - PubMed
  29. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  30. Nat Immunol. 2008 Aug;9(8):839-45 - PubMed
  31. Leukemia. 2010 Jun;24(6):1121-7 - PubMed
  32. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  33. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  34. J Proteomics. 2010 Sep 10;73(10):1907-20 - PubMed
  35. PLoS One. 2008;3(11):e3694 - PubMed
  36. Leukemia. 2009 Dec;23(12):2210-21 - PubMed

Publication Types